Non-natural amino acid replication-dependent microorganisms and vaccines

• US 9,121,024 B2
• Filed: 09/28/2009
• Issued: 09/01/2015
• Est. Priority Date: 09/26/2008
• Status: Active Grant

• Current Assignee: Ambrx, Inc. (Johnson & Johnson)
• Original Assignee: Ambrx, Inc. (Johnson & Johnson)
• Inventors: Tian, Feng, Hehli, Brad
• Primary Examiner(s): Nickol, Gary
• Assistant Examiner(s): SHAHNAN SHAH, KHATOL S
• Application Number:
  US13/120,255
• Publication Number:
  US 20110195483A1
• Time in Patent Office: 2,164 Days
• Field of Search: None
• US Class Current: 1/1
• CPC Class Codes: A61K 39/0258 Escherichia
• CPC Class Codes: A61P 31/04 Antibacterial agents
• CPC Class Codes: C12N 1/36 Adaptation or attenuation of cells
• CPC Class Codes: C12N 15/70 Vectors or expression systems specially adapted for E. coli
• CPC Class Codes: C12N 9/93 Ligases (6)

Abstract

Compositions and methods of producing vaccines, including methods wherein whole organism vaccines are provided with limited replication abilities, thereby increasing vaccine safety and efficacy, through the use of non-natural, unnatural, or non-naturally encoded amino acids.

Claims

1. A non-human animal vaccine, comprising a Mycobacterium avium subspecies paratuberculosis (MAP) cell and an adjuvant, wherein the MAP cell comprises a nucleotide sequence encoding an essential gene product that is required for replication, wherein the nucleotide sequence comprises a selector codon that codes for site-specific incorporation of a non-natural amino acid into the essential gene product, such as that the MAP cell replicates only in the presence of the said non-natural amino acid, and has limited or no replication capability in the absence of said non-natural amino acid.

2. The non-human animal vaccine of claim 1, wherein said MAP cell comprises more than one selector codon in the nucleotide sequence encoding the essential gene product for replication.

3. The non-human animal vaccine of claim 1, wherein said MAP cell comprises at least a second nucleotide sequence encoding a second essential gene product required for replication, wherein the at least second nucleotide sequence comprises at least one selector codon that codes for the site-specific incorporation of a non-natural amino acid in the second essential gene product for replication.

4. The non-human animal vaccine of claim 1, wherein the non-natural amino acid is selected from the group consisting of para-acetylphenylalanine, p-nitrophenylalanine, p-sulfotyrosine p-carboxyphenylalanine, an o-nitrophenylalanine an m-nitrophenylalanine a p-boronyl phenylalanine, an o-boronylphenylalanine, an m-boronylphenylalanine a p-aminophenylalanine an o-aminophenylalaninean m-aminophenylalanine, a p-acylphenylalanine, an o-acylphenylalanine, an m-acylphenylalanine, a p-OMe phenylalanine, an o-OMe phenylalanine an m-OMe phenylalanine a p-sulfophenylalanine an o-sulfophenylalanine an m-sulfophenylalanine, a 5-nitro His, a 3-nitro Tyr a 2-nitro Tyr, a nitro substituted Leu, a nitro substituted His, a nitro substituted De, a nitro substituted Trp, a 2-nitro Trp, a 4-nitro Trp, a 5-nitro Trp a 6-nitro Trp, a 7-nitro Trp, 3-aminotyrosine, 2-aminotyrosine, O-sulfotyrosine, 2-sulfooxyphenylalanine, 3 sulfooxyphenylalanine, o-carboxyphenylalanine, m-carboxyphenylalanine, p-acetyl-L-phenylalanine a p-propargyl-phenylalanine, O-methyl-L-tyrosine, an L-3-(2-naphthyl)alanine, a 3-methyl-phenylalanine, an O-4-allyl-L-tyrosine, a 4-propyl-L-tyrosine, a tri-O-acetyl-GlcNAcβ

-serine an L-Dopa, a fluorinated phenylalanine, an isopropyl-L-phenylalanine, a p-azido-L-phenylalanine, a p-acyl-L-phenylalanine, a p-benzoyl-L-phenylalanine, an L-phosphoserine, a phosphonoserine, a phosphonotyrosine, a p-iodo-phenylalanine, a p-bromophenylalanine, a p-amino-L-phenylalanine, an isopropyl-L-phenylalanine, and a p-propargyloxy-phenylalanine.

5. A method of inducing an immune response or reducing the risk of a bacterial infection, said method comprising administering to a non-human animal an effective amount of the non-human animal vaccine of claim 1.

6. The method of claim 5, wherein said bacterial infection is Johne'"'"'s disease.

7. The method of claim 5, wherein said non-human animal is selected from the group consisting of:

cow, pig, goat, sheep, horse, and dog.

8. A method of producing antibodies against Mycobacterium avium subspecies paratuberculosis (MAP), said method comprising administering to a non-human animal an effective amount of the non-human animal vaccine of claim 1 to produce antibodies against MAP.